Ridaforolimus: A promising drug in the treatment of soft-tissue sarcoma and other malignancies

Future Oncology

Volumn 7, Issue 7, 2011, Pages 827-839

  Dancey, Janet E ^b   Monzon, Jose ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

mTOR; ridaforolimus; sarcoma

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; BEVACIZUMAB; BICALUTAMIDE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DALOTUZUMAB; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; NAVELBINE; PACLITAXEL; RIDAFOROLIMUS; TOPOTECAN; TRABECTEDIN; TRASTUZUMAB; VORINOSTAT;

ADJUVANT THERAPY; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COLON FISTULA; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; ENDOMETRIUM CANCER; FATIGUE; HEADACHE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER TOXICITY; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEINURIA; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; SARCOMA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 79960142274     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.57     Document Type: Article

References (46)

1. Judson I. Targeted therapies in soft tissue sarcomas. Ann. Oncol. 21(Suppl. 7), VII277-VII280 (2010)
2. Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J. Cell. Mol. Med. 14(1-2), 42-50 (2010)
3. Ramanathan RC, A?Hern R, Fisher C, Thomas JM. Modified staging system for extremity soft tissue sarcomas. Ann. Surg. Oncol. 6(1), 57-69 (1999) (Pubitemid 29077489)
4. Dancey J. mTOR signaling and drug development in cancer. Nat. Rev. Clin. Oncol. 7(4), 209-219 (2010)
5. Chawla SP, Blay J-Y, Staddon AP et al. A Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcoma. Clin. Cancer Res. 11(24), Abstract 9068 (2005)
6. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst. Rev. (3), CD003293 (2003)
7. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma Meta-analysis Collaboration (SMAC). Cochrane Database Syst. Rev. (2), CD001419 (2000)
8. Sleijfer S, Ouali M, van Glabbeke M et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur. J. Cancer 46(1), 72-83 (2010)
9. Soini EJ, Garcia San Andres B, Joensuu T. Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information. Ann. Oncol. 22(1), 215-223 (2010)
10. Anderson SE, Keohan ML, D?Adamo DR, Maki RG. A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma 2006, 15947 (2006)
11. Dileo P, Morgan JA, Zahrieh D et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a Phase II trial. Cancer 109(9), 1863-1869 (2007) (Pubitemid 46668552)
12. Hensley ML. Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas. Curr. Opin. Oncol. 22(4), 356-361 (2010)
13. Le Cesne A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J. Clin. Oncol. 23(3), 576-584 (2005) (Pubitemid 46224235)
14. Lau L, Supko JG, Blaney S et al. A Phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children?s Oncology Group study. Clin. Cancer Res. 11(2), 672-677 (2005) (Pubitemid 40116894)
15. Pick AM, Nystrom KK. Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma. J. Oncol. Pharm. Pract. 16(4), 269-272 (2010)
16. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci. Signal 2(67), PE24 (2009)
17. Metcalf CA 3rd, Bohacek R, Rozamus LW et al. Structure-based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy. AACR Meeting Abstracts 45, Abstract 2476 (2004)
18. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol. 26(3), 361-367 (2008 (Pubitemid 351171685)
19. Hartford CM, Desai AA, Janisch L et al. A Phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin. Cancer Res. 15(4), 1428-1434 (2009
20. Fetterly GJ, Mita MM, Britten CD et al. Pharmacokinetics of oral deforolimus (AP23573, MK-8669). ASCO Meeting Abstracts 26(Suppl. 15), Abstract 14555 (2008
21. Clackson T, Metcalf CA, Rivera VM et al. Broad anti-tumor activity of AP23573, an mTOR inhibitor in clinical development. Proc. Am. Soc. Clin. Oncol. 22, Abstract 882 (2003)
22. Squillace R, Miller D, Clapham D et al. Anti-tumor activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) in sarcoma and endometrial cancer models and exploration of molecular correlates of sensitivity. AACR Meeting Abstracts 2008(Annual Meeting), Abstract 1482 (2008)
23. Squillace R, Miller D, Wardwell S, Wang F, Clackson T, Rivera V. Synergistic activity of the mTOR inhibitor deforolimus (AP23573; MK-8669) and the anti-androgen bicalutamide in prostate cancer models. 6(12), Abstract 103 (2008)
24. Haines B, Bittinger M, Chenard M et al. The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer. AACR Meeting Abstracts 2009(2 Annual Meeting), Abstract 1887 (2009)
25. Rivera VM, Tang H, Metcalf CA 3rd et al. Anti-proliferative activity of the mTOR inhibitor AP23573 in combination with cytotoxic and targeted agents. Proc. Am. Assoc. Cancer Res. 45, Abstract 3887 (2004)
26. Legrier M-E, D?Silva S, Yan H-G, Horwitz SB, McDaid HM. Chemosensitization by dual pharmacological inhibition of MEK and mTOR signaling pathways in human non-small cell lung cancer (NSCLC). AACR Meeting Abstracts 47, Abstract 4867 (2006)
27. McDaid HM, Legrier M, Yang CH et al. Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation. J. Clin. Oncol. 25(Suppl. 18), Abstract 10615 (2007)
28. Sathyanarayanan S, Jha S, Klinghoffer R et al. Combination treatment with the anti-IGF1R antibody MK-0646 and the mTOR inhibitor deforolimus leads to more effective PI3K pathway targeting and anti-tumor activity. AACR Meeting Abstracts 2009(2 Annual Meeting), Abstract 2809 (2009)
29. Mita MM, Britten CD, Poplin E et al. Deforolimus trial 106-A Phase I trial evaluating 7 regimens of oral deforolimus (AP23573, MK-8669). ASCO Meeting Abstracts 26(Suppl. 15), Abstract 3509 (2008)
30. Sessa C, Tosi D, Vigano L et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. Ann. Oncol. 21(6), 1315-1322 (2010)
31. Perotti A, Locatelli A, Sessa C et al. Phase Ib study of the mTOR inhibitor ridaforolimus with capecitabine. J. Clin. Oncol. 28(30), 4554-4561 (2010
32. Nemunaitis J, Hochster HS, Lustgarten S, Turner CD, Haluska F, Mita MM. Phase I trial of oral deforolimus in combination with bevacizumab in patients with advanced solid tumours. Eur. J. Cancer Suppl. 7(2), Abstract 1256 (2009)
33. Yardley D, Seiler M, Ray-Coquard I et al. Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter Phase 2 clinical trial. Presented at: The 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 10-13 December 2009
34. Chawla SP, Sankhala KK, Chua V et al. A Phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. ASCO Meeting Abstracts 23(Suppl. 16), Abstract 9068 (2005)
35. Chawla SP, Tolcher AW, Staddon AP et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of Phase II trial. ASCO Meeting Abstracts 25(Suppl. 18), Abstract 10076 (2007)
36. Chawla SP, Tolcher AW, Staddon AP et al. Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. ASCO Meeting Abstracts 24(Suppl. 18), Abstract 9505 (2006)
37. Sankhala KK, Chawla SP, Iagaru A et al.; for the AP23573 Sarcoma Study Group: Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET) scan. ASCO Meeting Abstracts 23(Suppl. 16), Abstract 9028 (2005)
38. Young H, Baum R, Cremerius U et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PETStudy Group. Eur. J. Cancer 35(13), 1773-1782 (1999) (Pubitemid 29512308)
39. Flanagan M. Details matter to ridaforolimus story. Biocentury 19(5), 6-7 (2011)
40. Colombo N, McMeekin S, Schwartz P et al. A Phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. ASCO Meeting Abstracts 25(Suppl. 18), Abstract 5516 (2007)
41. Rizzieri DA, Feldman E, Dipersio JF et al. A Phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 14(9), 2756-2762 (2008
42. Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116, 210-215 (2009
43. Ridaforolimus. Drugs R D 10(3), 165-178 (2010
44. American Cancer Society. Cancer Facts and Figures 2010 www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/ document/acspc-026238.pdf
45. ARIAD collaboration with Merck: SUCCEED trial www.ariad.com/wt/ tertiarypage/merck- collaboration
46. Registry and results database of clincal trials